BridgeBio reported strong sales performance and benefits from Trump-era tariffs and onshoring trends, according to TD Cowen.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BridgeBio reported strong sales performance and benefits from Trump-era tariffs and onshoring trends, according to TD Cowen.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BridgeBio
company in Palo Alto, United States
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- Tariffs are creating issues for the entire retail sector, involving Trump and Brian Cornell.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
Coverage
Newest first; wire copies grouped- Insider MonkeyTD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best Russell 2000 stocks to buy now. On August 6, TD Cowen reitera